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Abstract
Background: B cells exert their pathogenic action in rheumatoid arthritis (RA) locally in the synovium. This study
was undertaken to elucidate the chemokines responsible for the recruitment of B cells in the inflamed synovium,
taking into account that the rich chemokine milieu present in the synovial tissue can fine-tune modulate discrete
chemokine receptors.
Methods: Expression levels of chemokine receptors from the CC and CXC family, as well as CD27, were assessed by
flow cytometry in CD20+ mononuclear cells isolated from the peripheral blood (PB) and synovial fluid (SF) of RA
and psoriatic arthritis patients. Transwell experiments were used to study migration of B cells in response to a
chemokine or in the presence of multiple chemokines.
Results: B cells from the SF of arthritis patients showed a significant increase in the surface expression of CCR1,
CCR2, CCR4, CCR5 and CXCR4 with respect to PB. Conversely, SF B cells expressed consistently lower amounts of
CXCR5, CXCR7 and CCR6, independent of CD27 expression. Analysis of permeabilized B cells suggested
internalization of CXCR5 and CCR6 in SF B cells. In Transwell experiments, CCL20 and CXCL13, ligands of CCR6 and
CXCR5, respectively, caused a significantly higher migration of B cells from PB than of those from SF of RA patients.
Together, these two chemokines synergistically increased B-cell migration from PB, but not from SF.
Conclusions: These results suggest that CXCL13 and CCL20 might play major roles in RA pathogenesis by acting
singly on their selective receptors and synergistically in the accumulation of B cells within the inflamed synovium.
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Background
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA)
are systemic autoimmune diseases characterized by the
chronic inflammation of joints which leads to the
destruction of cartilage and bone [1]. Both T cells and B
cells are present in the inflammatory infiltrate of
synovial membranes in both diseases [1–3]. However,
clinical and experimental evidence indicates that B cells
play a dissimilar pathogenic role in RA and PsA;
specifically, B lymphocytes are not believed to be a
major factor in PsA pathophysiology, as they are in RA
[4–6]. Experimental data suggest that B cells ought to
migrate and accumulate in the synovial microenviron-
ment in order to exert their pathogenic action in RA
patients [7], through the local production of autoanti-
bodies and proinflammatory soluble factors, as well as
by acting as antigen-presenting cells [6, 8, 9]. However,
the driving force responsible for the recruitment of B
cells in the synovium of RA and PsA patients is not fully
clarified. A better understanding of the mechanisms
involved in the recruitment of B cells into inflamed syn-
ovial tissue might help identify potential therapeutic
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targets for the management of joint inflammatory pro-
cesses such as RA.
A number of chemokines, low molecular weight cyto-
kines, are produced locally in the target sites of
leukocyte trafficking and homing [10, 11]. There are cur-
rently described more than 50 chemokines and 20 G-
protein-coupled chemokine receptors [12]. Following the
binding of a chemokine to its receptor, intracellular
signal pathways lead to functional responses such as
chemotaxis, secretion and transcriptional activation
[12, 13]. Most leukocytes express more than one chemo-
kine receptor of varying promiscuity and are, in addition,
potentially capable of responding synergistically to con-
comitant migration signals [14]. Upon binding to their
ligands, chemokine receptors are rapidly internalized
following either a degradative or recycling pathway. This
mechanism, known as desensitization [15], limits the mag-
nitude and duration of signaling, thus protecting cells
from chemokine overstimulation [16].
In arthritis, several chemokines and their receptors are
involved in the process of leukocyte extravasation and
accumulation in the inflamed synovium [17], as well as in
the lymphoid tissue organization of synovial inflammatory
infiltrate [18, 19]. Several chemokines have been identified
in the synovial microenvironment of both RA [17, 20–22]
and PsA patients [23–25]. While the individual effects of
different chemokines are well known, the potential conse-
quences of the concomitant expression of chemokines
under pathologic conditions in vivo are still a matter of
debate [26]. With respect to B cells, one study found that
the chemokine system influences the development and in-
flammatory progression of B-cell-mediated autoimmune
diseases [27], and that a rich chemokine environment
strongly enhances in-vitro migration by an induced syner-
gism involving this cell type [28].
The objective of this work was to determine which
chemokines play the most relevant roles in the accumu-
lation of B cells in the synovium of patients with RA and
PsA. Based on CXCR5 and CCR6 internalization and
B-cell migration experiments, our results suggest that
CXCL13 and CCL20, the respective ligands of CXCR5
and CCR6, by acting synergistically, might participate in
the recruitment of B cells in the synovium in patients
with arthritis.
Methods
Patient and biological samples
Samples of peripheral blood (PB) and synovial fluid (SF)
were obtained from 12 and 13 patients with clinically
active RA and PsA, respectively (mean ± standard devi-
ation 28-joint Disease Activity Score (DAS28) erythro-
cyte sedimentation rate 4.31 ± 0.68 and 4.70 ± 0.55,
respectively). All patients met the American College of
Rheumatology/European League Against Rheumatism
classification criteria for RA [29] and the Classification
Criteria for Psoriatic Arthritis (CASPAR) [30]. Patients
attended our institution from December 2015 to June
2017, and were consecutively included in the study.
Table 1 presents the clinical characteristics of the
patients included in this study. PB and SF were simul-
taneously obtained by puncture of inflamed knees. All
patients gave informed consent, and the study was
approved by the Ethics Committee of Hospital Universi-
tario de Canarias (Tenerife, Spain). The expression level
of chemokine receptor in CD20+ PB mononuclear cells
from seven healthy voluntaries was used as control.
B cells from healthy donors were isolated by immunose-
lection (see later) using buffy coats provided by the Insti-
tuto de Hemodonación y Hemoterapia (Tenerife, Spain).
Cell isolation and culture
Mononuclear cells were isolated from heparinized PB
and SF samples by Biocoll (Biochrom AG, Berlin,
Germany) density-gradient centrifugation (300 × g, at
room temperature for 30 min). After washing in phos-
phate buffer without calcium and magnesium (PBS), B
cells were selected by anti-human CD20 or anti-human
CD19 fluorescein monoclonal antibodies for flow cytom-
etry analysis. For specific experiments, B cells were
isolated from the buffy coats of healthy donors by nega-
tive (StemCell Technologies Inc., Vancouver, Canada) or
positive (Miltenyi Biotec, Bergisch Gladbach, Germany)
immunoselection techniques, as indicated, using mag-
netic beads, resulting in a purity > 95%, which was ascer-
tained by positivity to CD19 or CD20 using flow
cytometric analysis.
Flow cytometry analysis
Surface labeling of chemokine receptors
Mononuclear cells freshly isolated from PB and SF were
simultaneously labeled with two directly conjugated mAbs
at 4 °C for 30 min. One of these was fluorescein isothio-
cyanate (FICT)-conjugated anti-human CD20mAb (2H7
clone; BD Pharmigen, Franklin Lakes, NJ, USA), which
was used to select the B-cell subset; and the other was ei-
ther a phycoerythrin (PE)-conjugated anti-human mAb
against CCR1 (53504 clone; R&D Systems, Minneapolis,
MN, USA), CCR2 (48607 clone; R&D), CCR3 (61828
clone; R&D), CCR4 (20540 clone; R&D), CCR5 (2D7
clone; BD Pharmigen) and CXCR4 (12G5 clone; BD
Pharmigen), or an allophycocyanin (APC)-conjugate anti-
human mAb against CCR6 (53101 clone; R&D), CCR7
(150503 clone; R&D), CXCR2 (6C6 clone; BD Pharmigen),
CXCR5 (51505 clone; R&D), CXCR6 (56811 clone; R&D)
and CXCR7 (358426 clone; R&D).
In selective experiments, mononuclear PB and SF cells
were simultaneously incubated with three monoclonal
antibodies directly conjugated to different fluorochromes
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for 30 min at 4 °C. An anti-human CD20 FITC mAb
(2H7 clone; BD Pharmigen) was used to select the B-cell
population combined with an anti-human CD27 PE
mAb (M-T271 clone; BD Pharmigen), to distinguish be-
tween memory (CD27+) and naïve (CD27–) B cells. Cells
were also simultaneously stained with human mAb
against CXCR4 APC (12G5 clone; BD Pharmigen),
CXCR5 APC (51505 clone; R&D), CXCR7 APC (11G8
clone; R&D) or CCR6 APC (REA190 clone; Miltenyi
Biotec). The fluorescence levels of isotype-matching
antibodies (ImmunoTools GmbH, Friesoythe, Germany)
were used as controls. After washing with PBS, at least
2 × 104 lymphocytes from each sample were analyzed
using an Accuri C6 flow cytometer (BD Biosciences) and
data were analyzed using BD Accuri C6 software.
Data of chemokine expression were presented as the
percentage of positive cells and mean fluorescence inten-
sity (MFI), using the fluorescence of isotype-matching
antibody as controls. Because fluorescence conditions
varied between experiments, the data were normalized
to express the relative mean fluorescence intensity
(rMFI) according to the equation:
rMFI ¼ MFISF–MFIisotype control
 
= MFIPB–MFIisotype control
   100:
Extracellular and intracellular labeling of chemokine
receptors
In selective experiments, the expression of CXCR4,
CXCR5 and CCR6 on CD20+ cells from PB and SF was
assessed in both nonpermeabilized (surface expression)
and permeabilized (total expression: surface plus
intracellular) lymphocytes using double labeling, as
described previously. Mononuclear cells were freshly
and rapidly isolated after extraction of PB and SF and
were maintained at 4 °C to avoid receptor internalization
[31]. Cells were permeabilized using a Cytofix/Cytoperm
permeabilization/fixation kit (BD Biosciences). After
Table 1 Clinical characteristics of patients
Patient Sex Age (years) Diagnosis Clinical pattern RF ACPA Time of evolution (years) Treatment CC dose (mg/day)
1 F 46 RA Polyarticular Pos Pos 11 Anti-TNF +MTX + PRED 5–10
2 F 55 RA Polyarticular Neg Neg 9 MTX 0
3 F 77 RA Polyarticular Pos Pos 8 MTX + OH CLQ + DEFL 6
4 F 51 RA Polyarticular Neg Neg 8 MTX 0
5 M 33 RA Polyarticular Neg ND 15 Anti-TNF +MTX 0
6 M 25 RA Polyarticular Neg Neg 0 None 0
7 M 17 RA Polyarticular Neg Neg 14 Anti-TNF +MTX 0
8 F 53 RA Polyarticular Pos Pos 16 MTX + PRED 7.5
9 F 62 RA Polyarticular Pos Pos 7 Anti-TNF +MTX + PRED 5
10 M 70 RA Polyarticular Neg ND 7 PRED 5
11 F 98 RA Polyarticular Pos Pos 11 Anti-IL-6 + PRED 5
12 M 71 RA Polyarticular Pos Pos 8 PRED 5
13 F 47 PsA Polyarticular Neg ND 16 MTX + NSAID 0
14 M 52 PsA Polyarticular Neg ND 12 MTX + DEFL 7.5
15 M 53 PsA Polyarticular Neg Neg 13 MTX + DEFL 15
16 M 53 PsA Polyarticular Neg Neg 13 MTX + DEFL 15
17 M 58 PsA Oligoarticular Neg Neg 0 None 0
18 F 39 PsA Polyarticular Neg ND 5 Anti-IL-17 0
19 F 31 PsA Polyarticular Neg ND 7 PRED 5
20 M 46 PsA Oligoarticular Neg Neg 6 PRED 7.5
21 F 32 PsA Polyarticular Neg ND 8 PRED 5
22 M 25 PsA Oligoarticular Neg Neg 0 None 0
23 M 55 PsA Oligoarticular Neg ND 6 Anti-TNF +MTX 0
24 M 54 PsA Polyarticular Neg Neg 7 Anti-TNF +MTX 0
25 F 65 PsA Oligoarticular Neg Neg 40 NSAID 0
ACPA anti-citrullinated peptide antibodies, CC corticosteroid, DEFL deflazacort, F female, IL interleukin, M male, MTX methotrexate, ND not determined, Neg negative,
NSAID nonsteroidal antiinflammatory drug, PsA psoriatic arthritis, Pos positive, PRED prednisone, OH CLQ hydroxycloroquine, RA rheumatoid arthritis, RF rheumatoid fac-
tor, TNF tumor necrosis factor
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washing, 3 × 104 lymphocytes from each sample were
analyzed using the Accuri C6 cytometer (BD Biosciences).
Data were normalized and expressed as rMFI, being the
surface or total expression of each chemokine receptor on
B cells from PB considered 100%.
Migration assays
Transwell experiments
The migration capacity of B-cells was studied using a
Transwell 96-well permeable support system with a
polycarbonate membrane with pores 3 μm in diameter
(Corning, NY, USA). CD19+ B cells were isolated by a
negative immunoselection process, using the EasySep™
Human CD19 Selection Kit (Stem Cell).
Chemoattractants and freshly isolated B cells (1.5 × 105
cells/well), both in RPMI 1640 supplemented with
20 mM HEPES, pH 7.4, and 0.5% bovine serum albumin
(BSA), were placed into the lower and upper wells,
respectively. To identify the optimum migration
concentration, dose–response assays were performed for
the recombinant human chemokines CXCL13 (R&D
Systems) and CCL20 (ImmunoTools, GmbH), using 10,
100 and 1000 nM. Then, increasing concentrations of
CXCL13 were used in the presence of the optimum
concentration of CCL20 and vice versa. As a control, the
anti-human CXCR5 blocking antibody (51505 clone;
R&D) was used at a concentration of 1.5 μg/ml in the
presence of 1000 nM CXCL13 alone, or in a mixture of
1000 nM CXCL13 plus 1000 nM CCL20. After 3 h of in-
cubation at 37 °C, the content of the lower compartment
was collected and the number of migrated cells was
analyzed in 50 μl of each sample using a medium acqui-
sition speed in the Accuri C6 cytometer.
The migration capacity of B cells from PB and SF of
arthritis patients was also studied using a Transwell six--
well system with pores 3 μm in diameter (Corning).
CXCL13, CCL20, CXCL12 and a mixture of CXCL13
and CCL20, all at 1000 nM, and freshly isolated mono-
nuclear cells (5 × 106 cells/well), both in medium as
described, were placed into the lower and upper wells,
respectively. After 3 h of incubation at 37 °C, the cells of
the lower compartment were labeled with anti-human
CD20 FITC for 30 min at 4 °C, washed in PBS and ana-
lyzed by flow cytometry. B-cell migration to the lower
well was assessed with respect to the total number of B
cells that were initially loaded into the upper well, iden-
tified by anti-CD20 FITC labeling of freshly isolated
mononuclear cells from PB or SF.
Statistical analysis
Differences between groups were analyzed for statistical
significance using the t test for paired (differences
between PB and SF in patients) or unpaired (differences
between patients and controls) samples. p < 0.05 was
considered significant. Results are expressed as the arith-
metic mean ± standard error (SE) of the mean.
Results
Chemokine receptors are differentially expressed on B
cells from PB and SF of RA and PsA patients
Chemokines and their receptors constitute a chemotac-
tic system that controls the migratory patterns and posi-
tioning of all immune cells [12]. To investigate the role
of this system in the migration of B cells to the inflamed
synovial tissue, we first studied by flow cytometry the
surface expression of a number of chemokine receptors
from the CC and CXC family on CD20+ mononuclear
cells isolated simultaneously from PB and SF of patients
with active RA and PsA. When the surface expression
level data expressed as rMFI were plotted, either by
disease diagnosis (Fig. 1a) or grouped (Fig. 1b),
significant increments of CCR1, CCR2, CCR4, CCR5
and CXCR4 were observed on CD20+ cells from SF with
respect to PB. Conversely, a significant and consistent
decrease in the surface expression of CXCR5, CXCR7
and CCR6 was detected in the B cells from SF compared
to PB, independent of whether the analysis examined the
diseases separately or together (Fig. 1a, b). The
expression profile of chemokine receptors on B cells
from PB and SF of RA patients was independent of RF
presence or absence (data not shown). Data of Fig. 1b
are also displayed in Additional file 1: Table S1 as the
raw MFI and percentage of positive cells. The
chemokine expression on PB B cells, as assessed by MFI
or proportion of positive cells, was not significantly
different between arthritic patients and healthy controls,
except for CCR6 which was significantly higher
expressed in B cells from patients than from controls.
These data demonstrate that B cells recruited in in-
flamed joints of RA and PsA patients modify in a similar
manner their basal surface expression profile of chemo-
kine receptors.
Synovial B cells increase CXCR4 and decrease CXCR5,
CCR6 and CXCR7 surface expression, independent of their
naïve or memory phenotype
The expression levels of several chemokine receptors are
regulated during cell differentiation and maturation [32].
Therefore, we studied the expression of CXCR4 (an
upregulated receptor) and CXCR5, CXCR7 and CCR6
(three downregulated receptors in SF B cells) on CD20+
cells from PB and SF depending on whether they had
been in contact (CD27+) or not (CD27–) with the
antigen [33]. Flow cytometry analysis showed a higher
percentage of memory (CD27+) versus naïve (CD27–) B
cells in SF (CD27+ 73 ± 3.66% versus CD27– 29 ± 3.21%,
p < 0.01) compared to PB (CD27+ 31 ± 3.89 versus
CD27– 70 ± 3.91, p < 0.01) with no differences found
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between RA and PsA patients. Triple-color flow cyto-
metric analysis showed that, in general, there were no
significant differences in the expression of these
chemokine receptors between CD27+ and CD27– B
lymphocytes from PB and SF of RA patients (Fig. 2).
Expression of CXCR4 showed a significant increase in
Fig. 1 Surface expression of chemokine receptors in CD20+ cells from PB and SF of RA and PsA patients. Mononuclear cells isolated from PB and SF
labeled with two fluorochrome-conjugated mAbs and analyzed by flow cytometry. a Surface expression of chemokine receptors in CD20+ B cells from
PB and SF of patients with RA (left) and PsA (right). Data represent mean ± SE of rMFI from six and five independent experiments, respectively.
Expression level of each chemokine receptor in PB B cells considered 100%. b Surface expression of chemokine receptors in CD20+ B cells from PB and
SF of patients with RA and PsA plotted together. Data represent mean ± SE of rMFI from 11 independent experiments. Representative flow cytometry
histograms showing surface expression of CXCR4, CXCR5, CXCR7 and CCR6 in CD20+ cells from PB and SF of patients with RA. Dotted histograms
represent isotype-matching control; dashed and closed histograms represent expression in B cells from PB and SF, respectively. *p < 0.05, **p < 0.01 by
t test for paired samples. PB peripheral blood, PsA psoriatic arthritis, RA rheumatoid arthritis, SF synovial fluid, rMFI relative mean fluorescence intensity
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CD27+ and CD27– cells from SF with respect to PB,
while there was a consistent decrease in the expression
of CXCR5, CCR6 and CXCR7 in SF B cells with respect
to PB, independent of their CD27 phenotype (Fig. 2).
Table 2 presents the differences in the absolute MFI
using flow cytometric analysis of CXCR4, CXCR5,
CXCR7 and CCR6 on CD27+ and CD27– B cells
between PB and SF from RA patients. Similar results
were obtained in PsA patients (data not shown).
These data show that expression profiles of the che-
mokine receptors CXCR4, CXCR5, CXCR7 and CCR6 in
synovial B cells, compared to those of PB, were not
modified by previous contact with the antigen.
Synovial B cells from RA patients internalize CXCR5 and
CXCR6 receptors
It is well established that the recognition of ligand by
chemokine receptors causes a decrease in their surface
expression due to receptor internalization [16]. B lym-
phocytes present in the SF of patients with active arth-
ritis showed a significant reduction of CXCR5 and CCR6
receptors. To determine whether this reduction was due
to an internalization mechanism, we used flow cytome-
try to study the expression of both receptors in nonper-
meabilized and permeabilized CD20+ cells from PB and
SF of RA patients. Our results showed that the
differences observed in CXCR5 and CCR6 on
nonpermeabilized cells (surface expression) between B
cells from PB and SF tended to disappear, or even
become inverted, when their expression was assessed in
permeabilized cells (total expression) (Fig. 3). This
relationship, when measured as a percentage of the
mean fluorescence intensities in nonpermeabilized
CD20+ cells, showed that CXCR5 and CCR6 surface
expression levels were 33 ± 5% and 76 ± 5% in SF with
respect to PB (considered 100%), respectively. However,
in permeabilized B cells the total expression of CXCR5
was equalized between SF (108 ± 5%) and PB, although
total expression of CCR6 in SF increased above that of
PB reaching 308 ± 35%. We also analyzed the surface
and total expression of CXCR4, a chemokine receptor
that increases its expression on B cells from the synovial
microenvironment. Surface expression of CXCR4
reached 180 ± 16% on SF B cells with respect to that of
PB, although in permeabilized B cells this difference in
the expression levels between the two compartments
was not observed.
These data suggest that CXCR5 and CCR6, but not
CXCR4, reduce their surface expression on synovial B
cells by internalization, a process that can be interpreted
in the context of desensitization to CXCL13 and CCL20,
but not to CXCL12.
Fig. 2 Surface expression of CXCR4, CXCR5, CXCR7 and CCR6 on
memory (CD27+) and naïve (CD27–) B cells from PB and SF of patients
with arthritis. Mononuclear cells isolated from PB and SF labeled with a
combination of three fluorochrome-conjugated mAbs and analyzed by
flow cytometry. Surface expression of chemokine receptors studied in
CD27+ and CD27– in CD20+ cells from PB (considered 100%) and SF in
patients with RA. Data expressed as mean ± SE of rMFI from seven
independent experiments compared to PB expression of each
chemokine receptor, considered 100%. *p< 0.05, **p< 0.01, ***p< 0.001
by t test for paired samples. rMFI relative mean fluorescence intensity,
PB peripheral blood, SF synovial fluid
Table 2 Chemokine receptor expression on memory (CD27+) and naïve (CD27–) CD20+ cells from SF and PB of patients with
rheumatoid arthritis
CXCR4 CXCR5 CXCR7 CCR6
CD27+ CD27– CD27+ CD27– CD27+ CD27– CD27+ CD27–
PB 1746 ± 177 3648 ± 247 p = 0.001 12,870 ± 719 16,028 ± 1102 p = 0.003 232 ± 36 349 ± 86 p = 0.15 10,243 ± 1143 10,130 ± 1792 p = 0.94
SF 4821 ± 1250 5880 ± 1531 p = 0.09 5568 ± 861 6239 ± 701 p = 0.26 105 ± 91 93 ± 25 p = 0.9 8040 ± 1041 6932 ± 1487 p = 0.37
p = 0.028 p = 0.14 p = 0.0001 p = 0.0001 p = 0.33 p = 0.04 p = 0.02 p = 0.005
Values are mean ± standard error of mean fluorescence intensity of each chemokine receptor on memory and naïve B cells from PB and SF. Bold data
statistically significant at p < 0.05
PB peripheral blood, SF synovial fluid
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Fig. 3 Surface and total expression of CXCR5, CCR6 and CXCR4 in B lymphocytes from PB and SF of patients with RA. Mononuclear cells isolated
from PB and SF labeled with a combination of two fluorochrome-conjugated mAbs and analyzed by flow cytometry. Surface (nonpermeabilized)
and total (permeabilized) expression of chemokine receptors studied in CD20+ cells from PB and SF of RA patients. Data expressed as mean ± SE
of rMFI from five independent experiments compared to PB expression of each chemokine receptor, considered 100%. Representative flow cytometry
histograms showing surface expression of CXCR5, CCR6 and CXCR4 in CD20+ cells from PB and SF of a patient with RA. Dotted histograms represent
isotype-matching control; dashed and closed histograms represent expression in B cells from PB and SF, respectively. **p< 0.01, t test for paired samples.
rMFI relative mean fluorescence intensity, PB peripheral blood, SF synovial fluid
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CXCL13 and CCL20 exert a synergistic effect on
B-lymphocyte migration
A synergistic effect has been described among several
chemokines in vitro and in vivo [34] resulting in in-
creased leukocyte migration [14]. Therefore, we studied
the chemoattractant capacity of CXCL13 and CCL20 on
B cells using transmigration assays.
B cells isolated from buffy coats of healthy donors
were used for Transwell experiments. The optimal cell
migration was obtained at 1000 nM CXCL13 and
1000 nM CCL20. When B cells were incubated at the
optimum concentration for CCL20 or CXCL13
(1000 nM) in combination with increasing concentra-
tions of the other chemokine (10, 100 or 1000 nM), a
clearly synergistic effect was observed in B-cell migra-
tion (five-fold increase), in particular when a mixture
containing 1000 nM of both chemokines was used as a
chemoattractant (Fig. 4a). The presence of a blocking
anti-CXCR5 monoclonal antibody in Transwell experi-
ments abrogated the transmigration effect of CXCL13
on B cells, either when it was used alone or in combin-
ation with CCL20 (Fig. 4b).
Synovial B cells from RA patients show a decreased
migration capability in response to CXCL13 and CCL20
compared to that from PB
The aforementioned results demonstrated that CXCL13
and CCL20 act synergistically in the migration of PB B
Fig. 4 CXCL13 and CCL20 exhibit synergistic effect on transmigration of B lymphocytes in vitro. a Migration in Transwell experiments of CD19+ B cells
from PB of healthy donors. Chemotaxis induced by presence of CXCL13 (open circles) and CCL20 (open diamonds), as well as by their combination at
different concentrations (filled circles). b Migration in Transwell experiments of CD19+ cells in presence of 1000 nM of CXCL13 or a combination of
1000 nM of CXCL13 and CCL20 in presence (black bars) or absence (gray bars) of blocking anti-CXCR5mAb. a, b Data represent absolute number of
migrated cells obtained in triplicate and expressed as mean ± SE of four independent experiments. c Migration of CD20+ cells from PB and SF of RA
patients. Data represent relative number of migrated B cells from PB and SF in Transwell experiments compared to basal conditions, considered 1.
Data expressed as mean ± SE of five independent experiments. *p < 0.05, by t test for paired samples. PB peripheral blood, SF synovial fluid
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cells from healthy donors. To determine whether B cells
from PB and SF of RA patients behave like those from
PB of healthy donors, mononuclear cells from patients
with RA were isolated and incubated in Transwells in
the presence of an optimal concentration (1000 nM) of
CXCL13 and CCL20 and with both chemokines in com-
bination. Fig. 4c shows that B cells from PB exert a
higher migration capability in the presence of CXCL13
and CCL20 than B cells from SF. The combination of
both chemokines showed a synergistic effect in PB from
RA patients, similar to that observed in healthy controls,
but not in SF B cells. Conversely, migration of B cells in
response to CXCL12 a ligand of CXCR4, was higher in B
cells from SF than from PB of RA patients.
These results suggest that CXCL13 and CCL20, acting
synergistically, are the main responsible driving force in
the migration and accumulation of B cells in the in-
flamed synovium of RA patients.
Discussion
The most important findings of this work can be sum-
marized as follows. B cells present in the synovial micro-
environment of patients with RA and PsA express the
chemokine receptors CXCR5, CCR6 and CXCR7, albeit
in significantly lower amounts than those in PB, inde-
pendent of disease type and their naïve or memory
phenotype. Also, this reduction in surface expression is
caused by internalization and not due to other forms of
downmodulation. Finally, CXCL13 and CCL20, the re-
spective ligands of CXCR5 and CCR6, show a synergistic
effect in driving the migration of PB B cells from healthy
donors and RA patients. Taken together, these results
strongly suggest that CXCL13 and CCL20, acting syner-
gistically, play a key role in the recruitment of B cells in
the inflamed synovium.
It has been reported that the accumulation of B cells
in the synovium plays an essential role in the pathogen-
esis of RA [7]. However, evidence suggests that this cell
type does not seem to play a major role in PsA patho-
genesis [4–6]. Once in the rheumatoid joint, B cells par-
ticipate in the pathogenesis of the disease through
different mechanisms [8, 9]. Although a wide variety of
chemokines and their receptors are expressed in the
synovium of RA [17, 20, 21] and PsA patients [23–25],
which of the chemokines present in the synovial micro-
environment play a predominant role in the accumula-
tion of B lymphocytes in the joints of these patients
remains to be fully clarified.
In order to investigate which chemokines play a major
role in the accumulation of B cells in the inflamed syno-
vium, we first studied the surface expression profile of
different chemokine receptors from the CC and CXC
family in B cells isolated from PB and SF. Our data
showed that the expression of chemokine receptors on B
cells present in the inflamed synovia is differentially
modulated, either positively or negatively, both in RA
and PsA patients. B cells from SF showed significant up-
regulation of CCR1, CCR2, CCR4, CCR5 and CXCR4, as
well as downregulation of CXCR5, CXCR7 and CCR6
surface expression compared to PB B cells in both
diseases. Different chemokine receptors have been
described on PB B cells from healthy individuals and
patients with autoimmune diseases, such as RA and sys-
temic lupus erythematosus (SLE) [35]. However, only
two studies have compared chemokine expression on B
cells from PB and SF, one in RA patients [36] and the
other in juvenile idiopathic arthritis (JIA) patients [37].
As with our own findings, the synovial B cells in these
two studies less often expressed CXCR5 and CCR6 com-
pared to PB. Our data for the proportion of B cells posi-
tive for CCR5, CCR6, CXCR4 and CXCR5 in both PB
and the synovial microenviroment from arthritic patients
and healthy controls are compatible with those described
previously by Nanki et al. [36]. However, although the
same mAb was used, Nanki et al.’s work show that more
than 60% of B cells from patients and controls express
CCR7, and ours show that this chemokine receptor is
much less expressed on B cells from both patients and
controls. As far as we know, a comparative analysis of
chemokine expression between B cells in PB and SF
from PsA patients has not been studied previously. In
addition, this marks the first time that the surface ex-
pression levels of CCR1, CCR3, CCR4 and CXCR7 have
been analyzed in SF and PB B cells from RA patients.
The expression of certain chemokine receptors is regu-
lated during cell differentiation and maturation [32, 38].
When B lymphocytes from RA patients were selected
based on their memory (CD27+) or naïve (CD27–)
phenotype, SF B cells expressed consistently lower levels
of CXCR5, CXCR7 and CCR6 and higher CXCR4 levels
compared to PB regardless of their prior contact with
the antigen. The study by Nanki et al. [36] analyzing the
percentage of positive cells, but not MFI, described
similar results, except for CXCR4 which was expressed
by 100% of B cells from both compartments, as was the
case in our own study.
Since chemokine receptors rapidly reduce their surface
expression upon ligand binding [16], it is reasonable to
think that the chemokine that causes the downregula-
tion of its receptor in the inflammatory foci should play
a relevant biological role; for instance and in our
context, in the recruitment of B cells to the joints. The
surface expression of CXCR5, CXCR7 and CCR6 were
decreased in SF B cells compared to PB. This finding is
consistent with a desensitization phenomenon, as a
consequence of receptor occupancy by their respective
ligands [16]: CXCL13, CXCL12 and CCL20, chemo-
kines that are present in the synovial
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microenvironment [17, 20, 21]. Interestingly, the
remaining receptors studied (CCR1, CCR2, CCR4,
CCR5 and CXCR4) showed an increased surface ex-
pression on SF B cells compared to PB, although
many of their respective ligands were also present in
the SF [17]. The explanation for this is elusive since
multiple regulatory mechanisms are involved in che-
mokine receptor signaling and expression [39, 40].
When we examined the differential expression of
CXCR5, CCR6 and CXCR4 on the cell surface and
total expression on B cells from the PB and SF of RA
patients, we observed that CXCR5 and CCR6 in SF B
cells had undergone an internalization process,
whereas CXCR4 had not. We interpreted these results
as follows: the receptors CXCR5 and CCR6 play a
predominant role in the migration of naïve B cells
and memory B cells to the inflamed synovium.
CXCL12 is a chemokine abundantly expressed in
the synovial tissue of RA patients [17]. Based on
migration experiments using PB B cells from healthy
donors, it has been proposed that CXCL12 might play
a relevant role in B-cell migration into the rheuma-
toid synovium [19, 36]. However, our results tended
toward a different direction; CXCR4 is strongly
upregulated on the cell surface of SF B cells, a find-
ing counter to the signaling by CXCL12 in these cells.
Furthermore, our data on CXCR7 regulation in SF B
cells go in the same direction. CXCR7 is an “atypical”
chemokine receptor that acts as a decoy receptor for
CXCL12 and CXCL11. The expression level of
CXCR7 was significantly lower in SF B cells than in
PB, suggesting that in the synovial microenvironment
this B-cell receptor sequesters CXCL12, consequently
reducing the availability of this chemokine for binding
with CXCR4.
CXCL13 and CCL20, specific ligands of CXCR5 and
CCR6, respectively, have been detected in the synovium
of patients with chronic arthritis [17, 21, 41]. CXCL13
has been described as the most effective chemoattractant
for B cells [42] and CCL20 as a selective chemoattract-
ant factor for lymphocytes [43] expressing CCR6 recep-
tors, such as naïve B cells [44]. Migration experiments
showed that these two chemokines are chemoattractant
for PB B cells from healthy donors. Synergistic effects
among several chemokines have been described in vitro,
which translates into increased leukocyte migration [14].
In this study, we present evidence of a novel positive
regulatory mechanism of leukocyte migration in which
the concomitant presence of adequate concentrations of
CXCL13 and CCL20 synergistically increases the chemo-
taxis of B cells in vitro. We postulate that this type of
synergy is mediated by dual receptors in which CXCR5
and CCR6 become activated following simultaneous or
sequential binding of their agonists [14]. However, this
issue should be confirmed by additional experimenta-
tion. Concurrently with these results, in Transwell ex-
periments B cells from the PB of RA patients migrated
to a significantly greater degree in the presence of
CXCL13 and CCL20 than at baseline, and synergistically
in the presence of both chemoattractants. However, the
ability of B cells from SF of these patients to migrate in
the presence of these chemokines was significantly lower
than that of PB, which suggests that on B cells CXCR5
and CCR6 undergo desensitization in the synovial
microenvironment. Conversely, B cells from SF showed
very high migration ability in response to CXCL12, even
higher than those from PB. This is an interesting finding
that suggests additional regulatory mechanisms for
CXCR4 expression and function, occurring in B cells mi-
grated to the inflamed synovial tissue. Although the data
obtained in both expression of receptors and migration
are very consistent among patients, a limitation of this
study is that the sample size does not allow the analysis
of patients according to the use of steroids or DMARDs.
Conclusions
Taken together, these results support the contention that
CXCL13 and CCL20, acting synergistically, may consti-
tute a key driving force for the migration and recruit-
ment of B lymphocytes in the inflamed synovium of
patients with arthritis. Given the relevant role that B
cells have shown in the pathogenesis of RA [9, 45], the
simultaneous interference of these two chemokines may
represent a novel therapeutic target for the management
of RA through the blockade of B-cell recruitment in the
rheumatoid synovium.
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